In contrast, those with evidence of heightened mPTP sensitivity or impaired NCLX function (e.g., advanced DCM) could be prioritized for trials with mPTP inhibitors or NCLX activators, respectively. This evidence concerns the gene SLC8B1 and familial dilated cardiomyopathy.